Thus, there are currently no drugs approved for JMML, and the only option is bone marrow transplantation with a success rate of only ~50% (Gupta et al, 2021); therefore, a molecular entity that inhibits mutant Shp2 is urgently needed. This evidence concerns the gene PTPN11 and juvenile myelomonocytic leukemia.